REG - e-Therapeutics plc - Total Voting Rights

E-TherapeuticsAnnouncement

31/10/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221031:nRSe3999Ea&default-theme=true

RNS Number : 3999E  e-Therapeutics plc  31 October 2022

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Total Voting Rights

 

 

 

London, UK, 31 October 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that in accordance with the
Financial Conduct Authority's Disclosure and Transparency Rules, the Company
has 582,114,982 ordinary shares of 0.1 pence each in issue, none of which are
held in treasury. Therefore, the total number of voting rights in the Company
is 582,114,982.

The above figure of 582,114,982 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company.

 

 

Enquiries:

 

 e-therapeutics plc                                 Tel: +44 (0)1993 883 125
 Ali Mortazavi, CEO                                 www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

 SP Angel Corporate Finance LLP                     Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets and design RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 ETX's proprietary Computational Biology Platform enables the generation and
analysis of biological network models, providing a novel and mechanistic
approach to drug discovery that explicitly considers the true complexity of
biology and makes more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive
and integrated hepatocyte-centric data and information resource.   The
Company generates, prioritises and tests millions of hypotheses in silico to
identify better therapeutic targets with higher confidence.

 ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes
in the liver and the specific silencing of novel disease-associated genes,
identified by ETX's Computational Biology Platform.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 ETX is progressing a pipeline of first-in-class pre-clinical RNAi
candidates in several therapeutic areas including haematology, cardiovascular
disease and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered
with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach across a
diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the AIM Market of the London
Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded
on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol
ETXPF.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRDZMZGKNMGZZM